2018-10-182018-10-181932620310.1371/journal.pone.0122987http://hdl.handle.net/11285/630522Thyroid hormone receptor (TR) agonists have been proposed as therapeutic agents to treat non-alcoholic fatty liver disease (NAFLD) and insulin resistance. We investigated the ability of the TR agonists GC-1 and KB2115 to reduce hepatic steatosis in ob/ob mice. Both compounds markedly reduced hepatic triglyceride levels and ameliorated hepatic steatosis. However, the amelioration of fatty liver was not sufficient to improve insulin sensitivity in these mice and reductions in hepatic triglycerides did not correlate with improvements in insulin sensitivity or glycemic control. Instead, the effects of TR activation on glycemia varied widely and were found to depend upon the time of treatment as well as the compound and dosage used. Lower doses of GC-1 were found to further impair glycemic control, while a higher dose of the same compound resulted in substantially improved glucose tolerance and insulin sensitivity, despite all doses being equally effective at reducing hepatic triglyceride levels. Improvements in glycemic control and insulin sensitivity were observed only in treatments that also increased body temperature, suggesting that the induction of thermogenesis may play a role in mediating these beneficial effects. These data illustrate that the relationship between TR activation and insulin sensitivity is complex and suggests that although TR agonists may have value in treating NAFLD, their effect on insulin sensitivity must also be considered. © 2015 Martagón et al.info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0eprotiromehormone receptor stimulating agentliothyroninesobetiromethyroid hormone receptorthyroid hormone receptor agonisttriacylglycerolunclassified drug3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acidacetic acid derivativeanilideglucose 6 phosphataseglucose blood levelphenol derivativesobetiromethyroid hormone receptoranimal experimentanimal modelanimal tissueArticlebody temperaturecontrolled studyglucose blood levelglucose toleranceglycemic controlinsulin resistanceinsulin sensitivityliver levelmalemousenonalcoholic fatty livernonhumanob/ob mouseagonistsanimalbiosynthesisdose responsedrug effectsenzyme inductioninsulin resistancemetabolismmouse mutantNon-alcoholic Fatty Liver Diseasetime factorMusAcetatesAnilidesAnimalsBlood GlucoseBody TemperatureDose-Response Relationship, DrugEnzyme InductionGlucose-6-PhosphataseInsulin ResistanceMaleMiceMice, ObeseNon-alcoholic Fatty Liver DiseasePhenolsReceptors, Thyroid HormoneTime Factors7 INGENIERÍA Y TECNOLOGÍAArtículo104